120 related articles for article (PubMed ID: 10450539)
21. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
22. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII.
Bröijersén A; Hamsten A; Silveira A; Fatah K; Goodall AH; Eriksson M; Angelin B; Hjemdahl P
Thromb Haemost; 1996 Aug; 76(2):171-6. PubMed ID: 8865525
[TBL] [Abstract][Full Text] [Related]
23. Procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II.
Atta M; Crook D; Shafique F; Johnston DG; Godsland IF
Thromb Haemost; 2008 Sep; 100(3):391-6. PubMed ID: 18766253
[TBL] [Abstract][Full Text] [Related]
24. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
25. [Fibrinogen and factor VII in women with dyslipidemia. The preliminary results of the Bellvitge-Costa de Ponent Study. The Bellvitge Study Group].
Val A; Espínola A; Domenech P; Argimón JM; Castells A; Pintó X; Fiol C
Med Clin (Barc); 1995 Jul; 105(5):161-3. PubMed ID: 7630226
[TBL] [Abstract][Full Text] [Related]
26. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
27. Apolipoproteins A-I and B-markers in coronary risk evaluation.
Agoston-Coldea L; Zdrenghea D; Pop D; Crăciun A; Rusu ML; Mocan T
Rom J Intern Med; 2007; 45(3):251-8. PubMed ID: 18333357
[TBL] [Abstract][Full Text] [Related]
28. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Emmerich KH; Poritis N; Stelmane I; Klindzane M; Erbler H; Goldsteine J; Görtelmeyer R
Klin Monbl Augenheilkd; 2009 Jul; 226(7):561-7. PubMed ID: 19644802
[TBL] [Abstract][Full Text] [Related]
30. [Long-term treatment of hyperlipoproteinemia with etofibrate].
Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
32. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2.
de Luis DA; Fernandez N; Arranz ML; Aller R; Izaola O; Romero E
J Diabetes Complications; 2005; 19(1):42-6. PubMed ID: 15642489
[TBL] [Abstract][Full Text] [Related]
33. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Velussi M
Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
[TBL] [Abstract][Full Text] [Related]
34. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
Skwarek M; Bilińska ZT; Mazurkiewicz Ł; Grzybowski J; Kruk M; Kurjata P; Piotrowski W; Ruzyłło W
Kardiol Pol; 2008 May; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
[TBL] [Abstract][Full Text] [Related]
35. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of selected risk factors of atherosclerosis in children with type 1 diabetes mellitus and hypercholesterolemia].
Muchacka-Bianga M; Deja G; Jarosz-Chobot P; Małecka-Tendera E; Kalina M; Grychtoł M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):25-30. PubMed ID: 16704858
[TBL] [Abstract][Full Text] [Related]
37. [Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy].
Broncel M; Marczyk I; Kostka B; Michalska M; Sikora J; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Jan; 22(127):21-4. PubMed ID: 17477084
[TBL] [Abstract][Full Text] [Related]
38. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
39. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
Elgzyri T; Castenfors J; Hägg E; Backman C; Thorén M; Bramnert M
Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
[TBL] [Abstract][Full Text] [Related]
40. [The relationships between the lipoprotein profile and rheological-coagulation parameters in patients with hyperlipoproteinemia type II].
Bo M; Molaschi M; Neirotti M; Bonino F; Gottero M; Pedrazzini V; Mainardi S; Fabris F
Recenti Prog Med; 1992 Apr; 83(4):189-93. PubMed ID: 1626110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
